What is Esperion Therapeutics's long-term debt, net?

Esperion Therapeutics (ESPR) reported long-term debt, net of $97.39M in Q1 2026.

How has Esperion Therapeutics's long-term debt, net changed year-over-year?

Esperion Therapeutics's long-term debt, net increased by 0.5% year-over-year, from $96.87M to $97.39M.

What is the long-term trend for Esperion Therapeutics's long-term debt, net?

Over 5 years (2020 to 2025), Esperion Therapeutics's long-term debt, net has grown at a -11.5% compound annual growth rate (CAGR), from $179.37M to $97.26M.

Esperion Therapeutics ESPR Long-term debt, net

Long-term debt, net at other companies

Datadog, Inc.DDOG

$984.5M+0.4%

Mirion TechnologiesMIR

$443.5M—

Fulton FinancialFULT

$5.72M-41.5%

International PaperIP

$9.1B-5.2%

ServiceNowNOW

$1.49B+0.1%

Blue Bird CorporationBLBD

$85.32M-5.2%

Other financials

Income statement

See full

Revenue$80.1M+23.2%

Operating income-$6.6M+70.2%

Net income-$25.2M+37.7%

EPS (diluted)-$0.10+52.4%

Balance sheet

See full

Cash & equivalents$156.2M+36.2%

Total debt$155.2M+6.1%

Total equity-$307.9M+27.8%

Total assets$462.5M+42.7%

Cash flow

See full

Operating cash flow-$27.7M-22.5%

CapEx$189.0K—

Free cash flow-$27.9M-23.3%

Valuation

See full

Market cap$811.73M+283%

Enterprise value$810.81M+233%

P/S1.9×+1.1×

Profitability

See full

Operating margin18.1%+12.7pp

Net margin-34.8%+8.0pp

FCF margin-30.7%—

Returns & leverage

See full

Return on equity-260.8%—

Debt / equity0.8×—

Current ratio1.5×+0.4×

Where this comes from

Reported directly by Esperion Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ConvertibleLongTermNotesPayable.

The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Esperion Therapeutics's long-term debt, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Esperion Therapeutics's long-term debt, net?: Esperion Therapeutics (ESPR) reported long-term debt, net of $97.39M in Q1 2026.
How has Esperion Therapeutics's long-term debt, net changed year-over-year?: Esperion Therapeutics's long-term debt, net increased by 0.5% year-over-year, from $96.87M to $97.39M.
What is the long-term trend for Esperion Therapeutics's long-term debt, net?: Over 5 years (2020 to 2025), Esperion Therapeutics's long-term debt, net has grown at a -11.5% compound annual growth rate (CAGR), from $179.37M to $97.26M.